Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
4
Neutral
4
Bullish
6
Bearish
4
Neutral
4
Bullish
38
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stock
RPG Life Sciences is a research-focused pharmaceutical company engaged in the development and marketing of formulations and APIs in both domestic and international markets.
The company displayed a modest revenue growth of 4.0% in the 9M FY26 compared to the same period last year, although profit margins contracted due to increased expenditures.
RPG Life Sciences is actively pursuing strategic capacity expansions and modernization of its manufacturing facilities, backed by a capex of ₹140 crore, to support its growth objectives.
The company leverages a diversified product portfolio catering across several therapeutic segments like nephrology, oncology, cardiology, and more, with strong emphasis on chronic and specialty therapies.
With zero debt and a reinforced balance sheet, the company secured a strong credit rating reaffirmation from ICRA, indicating robust financial health and sustainable growth.
Pharmaceuticals & Biotechnology
Pharmaceuticals
4,818 Cr
Low Risk
43.9
36.7
—
8.0
3,080.90
1,731.25
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Upcoming Result Date: Jul 27, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
RPG Life Sciences Ltd (RPGLIFE) is currently trading at 3,016.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
RPG Life Sciences is a research-focused pharmaceutical company engaged in the development and marketing of formulations and APIs in both domestic and international markets. The company displayed a modest revenue growth of 4.0% in the 9M FY26 compared to the same period last year, although profit margins contracted due to increased expenditures. RPG Life Sciences is actively pursuing strategic capacity expansions and modernization of its manufacturing facilities, backed by a capex of ₹140 crore, to support its growth objectives. The company leverages a diversified product portfolio catering across several therapeutic segments like nephrology, oncology, cardiology, and more, with strong emphasis on chronic and specialty therapies. With zero debt and a reinforced balance sheet, the company secured a strong credit rating reaffirmation from ICRA, indicating robust financial health and sustainable growth.
Over the past 52 weeks, RPG Life Sciences Ltd has traded between a low of ₹1,731.25 and a high of ₹3,080.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
RPG Life Sciences Ltd has a market capitalization of approximately 4,817.82. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
RPG Life Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 43.93 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 4,817.82 Cr, RPG Life Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
RPG Life Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of RPG Life Sciences Ltd is 43.93. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Paste the full source article text here (or share a link plus the text). Without the text, I cannot extract facts or numbers reliably.
Shareholders approved a final dividend of ₹24 per equity share for the financial year ended March 31, 2026.
Managing Director Ashok Nair said the company is close to acquiring a “major API asset”, while noting that API asset valuations remain elevated.
The stock rose after the company announced Q4 and FY results and its board recommended a ₹24 per share dividend for FY26.
AGM/EGM Notice
RPG Life Sciences Ltd held its 19th AGM on 2026-07-23; all resolutions passed, audited FY2025-26 financials adopted and a dividend of ₹24 per share declared; scrutinizer's report and voting results submitted.
AGM/EGM Notice
RPG Life Sciences Ltd: 19th AGM held on July 23, 2026. All resolutions passed, including adoption of audited standalone & consolidated FY2025-26 financial statements and declaration of dividend ₹24/share (300%). Meeting ended 15:38.
Board Meeting
RPG Life Sciences notified exchanges that its Board will meet on 2026-07-28 to consider and approve unaudited standalone and consolidated financial results for quarter ended June 30, 2026; trading window closed July 1 until 48 hours after results.
Board Meeting
RPG Life Sciences will hold a Board meeting on 2026-07-28 to consider and approve unaudited standalone and consolidated financial results for the quarter ended 2026-06-30; trading window closed from 2026-07-01 until 48 hours after results.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
951.05 | 5,401 Cr | 38.47 | 4.95 | 0.21 | 12.92 | 14.30 | 7.67 | ||
992.00 | 5,011 Cr | 184.65 | 3.89 | 0.00 | 2.11 | 2.48 | 1.10 | ||
461.00 | 4,916 Cr | 37.26 | 4.12 | 0.22 | 10.82 | 16.48 | 9.03 | ||
3016.80 | 4,818 Cr | 43.93 | 7.96 | 0.82 | 19.03 | 24.66 | 14.52 | ||
149.40 | 4,385 Cr | 30.06 | 2.44 | 0.67 | 7.65 | 10.29 | 5.32 | ||
1258.40 | 4,358 Cr | — | 6.28 | 0.08 | -10.66 | -6.48 | -6.55 | ||
1657.35 | 4,067 Cr | 41.60 | 4.97 | 0.00 | 11.39 | 15.94 | 9.99 | ||
| Median: 7 Co. | — | 992.00 | 4,818 Cr | 40.03 | 4.95 | 0.21 | 10.82 | 14.30 | 7.67 |
